IMMUNOTHERAPY FOR CANCER
Immune Checkpoint Inhibitors for Cancer
Immune checkpoints refer to inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. Here at the Silver Cancer Institute we use immunotherapy to help you recover from your cancer. In addition to low dose chemotherapy and natural substances.
New recent peer reviewed medical literature concerning immunotherapy
Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutic to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.Read More
These drugs are known as immune checkpoint blockades and they are designed to circumvent the ways in which cancer staves off an immune response. The immune system has a number of checkpoints — mechanisms that help to prevent it from getting out of control and attacking the body’s own cells. The checkpoints act much like the brakes on a car: even if the immune system is trying to prompt its T cells into action, the checkpoints suppress the activation. Tumors can turn on these checkpoints and prevent a T-cell attack, but immune checkpoint blockades take the brakes off the T cells, freeing them to fight the malignancy.
In 2011, the US FDA approved the anti- CTLA-4 drug ipilimumab (developed by Bristol-Myers Squibb and marketed as Yervoy). Mouse studies suggested that ipilimumab wouldn’t work well by itself and would need to be combined with other drugs to show any significant effect. But the first patients responded to ipilimumab even better than the mice had.
Supportive Oligonucleotide Technique (SOT)
A similar technique called antisense has been known to have been used for at least 15 years; however, there are major differences between antisense as traditionally used and SOT.
SOT has the ability to induce apoptosis (cell death) in the circulating cancer stem cells and circulating cancer tumor cells, and all primary and metastatic tumors. This is regardless of the size and most notably it is able to cross the blood brain barrier with ease. The SOT will remain active in the blood stream for approximately 14-16 weeks, but may be longer per dose. Because, the messenger RNA actually features a stealth like ability that keeps the body from recognizing and destroying it, only 3 SOT doses are allowed in any 12-month period. Also, we can use SOT therapy for any type of infection including Lyme, mold, and HIV, etc.
Immunotherapy therapy, also called biologic therapy, is a type of cancer treatment designed to boost the body's natural defenses to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune function. It works in the following ways:
- Stopping or slowing the growth of cancer cells.
- Stopping cancer from spreading to other parts of the body.
- Helping the immune system work better at destroying cancer cells.
When indicated we use immunotherapy in all our patients. In addition to this we use low dose chemotherapy and natural substances.
Please call us for more information (480) 860-2030.
Dean R. Silver, M.D., M.D. (H)